Compare Huntington Bancshares Incorporated (HBAN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Recursion Pharmaceuticals Inc — how do they compare? Huntington Bancshares Incorporated trades at $15.26 (market cap $31.04B), while Recursion Pharmaceuticals Inc trades at $4.09 (market cap $2.14B). The key difference: Huntington Bancshares Incorporated is far larger — about 14.5× Recursion Pharmaceuticals Inc's market cap, and Huntington Bancshares Incorporated pays a 4.04% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Bancshares Incorporated for 52 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| HBAN | RXRX | |
|---|---|---|
Market Cap | $31.04B | $2.14B |
Volume | 23,864,172 | 30,789,535 |
Sector | Financials | Health |
52-Week High | $19.27 | $6.79 |
52-Week Low | $15.02 | $2.84 |
Typical Hold Time | 52 Days | 22 Days |
Enterprise Value | $49.57B | $1.66B |
Dividend Yield | 4.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $15.17, down 1.04% on the day, with a bearish technical signal. The company reported mixed quarterly earnings, missing in Q4 2025 and Q2 2026 but beating in Q1 2026, while revenue grew to $8.13B in 2025. Analyst consensus is split evenly between Buy and Hold, with a $19.60 price target suggesting upside. Recent news highlights margin pressures from higher interest rates and a revised 2027 outlook.
HBAN offers value with a P/E of 11.82 and pays a dividend, but faces headwinds from net interest margin compression and loan growth challenges. The stock's near-term performance hinges on Q3 2026 earnings and management's ability to navigate rate environment pressures.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
